The development history of new biomarkers for hepatitis B virus infection / 临床肝胆病杂志

ABSTRACT

The objective of antiviral therapy for chronic hepatitis B is to maximize the long-term inhibition of hepatitis B virus (HBV) replication, reduce hepatocyte inflammation and liver fibrosis, and delay and reduce liver failure, decompensated cirrhosis, hepatocellular carcinoma, and other complications. In addition to serum HBV DNA which has been used for a long time, new biomarkers such as intrahepatic HBV cccDNA, serum HBcrAg, serum HBV RNA, serum HBsAg, and serum anti-HBc are commonly used in recent years to evaluate antiviral response in clinical practice, and their clinical value has attracted more and more attention. Such biomarkers have important clinical significance in monitoring and evaluating antiviral response and predicting the risk of viral rebound after drug withdrawal and the risk of hepatocellular carcinoma.